Eton Pharmaceuticals (ETON) Preferred Stock Liabilities (2017 - 2018)
Eton Pharmaceuticals (ETON) reported Preferred Stock Liabilities of $21.2 million for Q3 2018, up 11.35% sequentially from $19.0 million in Q4 2017.
Eton Pharmaceuticals (ETON) Preferred Stock Liabilities (2017 - 2018) Analysis & Trends
Eton Pharmaceuticals (ETON) has 2 years of Preferred Stock Liabilities data on file, last reported at $21.2 million in Q3 2018.
- For the quarter ending Q3 2018, Preferred Stock Liabilities changed N/A year-over-year to $21.2 million; the trailing twelve-month figure through Sep 2018 stood at $21.2 million (changed N/A YoY), and the FY2017 full-year result was $19.0 million, changed N/A from the prior year.
- Preferred Stock Liabilities climbed to $21.2 million in Q3 2018, from $19.0 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $21.2 million in Q3 2018 to a low of $19.0 million in Q4 2017.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Eton Pharmaceuticals | 1.19 Bn | 1.16 Bn | 13.10 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 21.16 Mn |
| Dec 31, 2017 | 19.00 Mn |